IceCure Begins Postmarket Study of ProSense Cryoablation for Breast Cancer

October 26, 2026—IceCure Medical Ltd., developer of minimally invasive cryoablation technology, announced the enrollment of the first two patients at United States clinical sites in the postmarketing study evaluating ProSense cryoablation for the local treatment of low-risk breast cancer.

SPIRARE II Results Published for Jupiter’s Vertex Thrombectomy System

October 20, 2026—Jupiter Endovascular, Inc. announced that the full results of the SPIRARE II pivotal trial, evaluating the company’s Vertex thrombectomy system in patients with acute, intermediate-risk pulmonary embolism (PE), were published in EuroIntervention by Sameh Sayfo, MD, et al.

Penumbra’s CAVT Technology Cleared for DVT Indication

October 20, 2026—Penumbra, Inc. announced that the FDA has granted clearance for the treatment of deep vein thrombosis (DVT) to the company’s Lightning computer-assisted vacuum thrombectomy (CAVT) technology.

FDA Approves Haemonetics PerQseal Elite Vascular Closure System

October 20, 2026—Haemonetics Corporation announced FDA approval of the PerQseal Elite vascular closure system for large-bore arterial procedures.

Subgroup Analysis From PERFORMANCE II Presented for Neuroguard IEP Carotid Stent System

October 16, 2026—At VIVA 2026, the Vascular InterVentional Advances conference, William A. Gray, MD, presented findings from a subgroup analysis of the PERFORMANCE II pivotal trial for the Neuroguard integrated embolic protection (IEP) 3-in-1 carotid stent system (Contego Medical LLC, distributed in the United States by Medtronic), which uses dual filtration and a purpose-built carotid stent&; In March 2026, Dr. Gray presented the 3-year outcomes from the trial at ISET.

BD’s Rotarex to Treat CLTI Evaluated in Interim Findings from XTRACT Registry 

October 16, 2026—Interim findings from the prospective, international XTRACT registry for the Rotarex rotational excisional atherectomy system (Becton, Dickinson and Company [BD]) in patients with chronic limb-threatening ischemia (CLTI) were presented by Prakash Krishnan, MD, at VIVA 2026, the Vascular Interventional Advances conference.

ELEGANCE Registry Reports 12-Month Eluvia DES Outcomes in Complex PAD

October 16, 2026—The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated endovascular treatment of peripheral artery disease (PAD) with the Ranger drug-coated balloon or Eluvia drug-eluting stent (DES; both Boston Scientific Corporation).

PROMISE III Reports 1-Year Outcomes With TADV Using the LimFlow System

October 16, 2026—One-year results from the prospective, multicenter, single-arm PROMISE III trial evaluated transcatheter arterialization of the deep veins (TADV) with the LimFlow system (Stryker Peripheral Vascular) in patients with chronic limb-threatening ischemia (CLTI).